XLO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	143 939
Average Volume	1.21M
Market Cap	40.23M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.300 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.00800 (0.72%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Gilead Sciences, Inc.	Buy	485 250	Common Stock
2024-04-02	Gilead Sciences, Inc.	Buy	3 882 450	Prefunded Warrants (right to buy)
2024-03-27	Gilead Sciences, Inc.	Sell	0	Common Stock
2024-02-08	Atlas Venture Fund Xi, L.p.	Sell	733	Common Stock
2024-02-08	Atlas Venture Fund Xi, L.p.	Sell	267	Common Stock

INSIDER POWER
91.68
Last 95 transactions
Buy: 18 066 351 \| Sell: 51 747 162

Volume Correlation

Long: 0.01 (neutral)

Short: 0.04 (neutral)

Signal:(71.985) Neutral

Xilio Therapeutics, Inc. Correlation

10 Most Positive Correlations
AMRB	0.872
OTRK	0.864
NEON	0.858
SHYF	0.843
PPTA	0.841
POET	0.825
UBFO	0.825
LWAC	0.82
PBPB	0.82
NVCN	0.819

10 Most Negative Correlations
TUEM	-0.819
STAB	-0.818
CFV	-0.812
AHPI	-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xilio Therapeutics, Inc. Correlation - Currency/Commodity

0.47
( neutral )

0.54
( weak )

0.00
( neutral )

-0.40
( neutral )

Xilio Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.90M (0.00 %)
EPS:	$-2.78

FY	2023
Revenue:	$0
Gross Profit:	$-1.90M (0.00 %)
EPS:	$-2.78

FY	2022
Revenue:	$0
Gross Profit:	$-1.85M (0.00 %)
EPS:	$-3.19

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-13.52

Financial Reports:

No articles found.

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.